Hers Clinical Gaps and Limitations: What the Platform Misses

Is Hers a Legitimate Medical Platform?

Hers operates legally under U.S. State telehealth statutes and employs licensed clinicians. Prescriptions are issued by real providers. The platform is not a scam in any regulatory sense. The more useful question is whether its clinical workflows meet the standards patients would receive from a traditional endocrinologist or ob-gyn, and on several measures they do not.

The FDA does not certify telehealth platforms for clinical quality. That responsibility falls to state medical boards, and enforcement is uneven. Hers has not published peer-reviewed outcome data for any of its treatment categories as of mid-2025. That absence is not unique to Hers, but it matters when evaluating whether subscriptions translate into measurable health improvements.

What Hers Prescribes

Hers offers prescriptions across four broad areas: hormone therapy for menopause and perimenopause, GLP-1 receptor agonists for weight loss, mental health medications (primarily SSRIs and SNRIs), and topical or oral hair-loss treatments. Each category carries its own evidence base and monitoring requirements, and the platform's handling of those requirements varies considerably.

Regulatory and Prescribing Model

Clinicians on Hers can prescribe after an asynchronous intake questionnaire or a short synchronous video visit. Neither pathway requires a physical exam. The Ryan Haight Online Pharmacy Consumer Protection Act generally requires at least one in-person evaluation before prescribing controlled substances, but most Hers medications fall outside that category. The practical result is that a patient can receive a hormone or GLP-1 prescription within 24 to 48 hours of completing a web form.

Hers Women's HRT: What the Evidence Says About Monitoring

Hormone therapy for menopausal symptoms is one of the most evidence-supported treatments in women's health. The 2023 Menopause Society (formerly NAMS) position statement states that "for women aged younger than 60 years or within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks for treatment of bothersome vasomotor symptoms" (Menopause Society, 2023). The science supports prescribing. The gap at Hers is monitoring, not prescribing.

Baseline Lab Requirements

Standard ob-gyn and endocrinology practice includes baseline estradiol, FSH, and TSH levels before initiating HRT, along with a lipid panel for cardiovascular risk stratification. Hers does not uniformly require these labs before issuing a prescription. A patient with undiagnosed hypothyroidism, for example, might receive estrogen therapy when her primary symptom driver is a thyroid disorder. A 2021 analysis in the Journal of Clinical Endocrinology and Metabolism found that thyroid dysfunction was present in 8.3% of perimenopausal women seeking HRT, a cohort large enough that the omission of TSH testing is clinically consequential.

Dose Titration Without Biomarkers

The Women's Health Initiative trials (N=16,608) established that estrogen-plus-progestin combinations carry a statistically detectable increase in breast cancer risk at five or more years of use (hazard ratio 1.26, 95% CI 1.00 to 1.59) (Rossouw et al., JAMA 2002). Minimizing unnecessary exposure therefore depends on titrating to the lowest effective dose, which in turn depends on tracking serum estradiol levels. Without mandated follow-up labs, Hers clinicians are titrating on symptom reports alone. Symptom-guided titration can work, but it is more likely to overshoot or undershoot the therapeutic target than biomarker-guided titration.

Compounded vs. FDA-Approved Formulations

Hers sometimes prescribes compounded bioidentical hormones alongside FDA-approved products. The FDA has stated clearly that compounded hormone preparations have not been evaluated for safety or efficacy and should not be considered equivalent to approved therapies (FDA, 2022). Patients selecting compounded options through Hers may not fully understand that distinction.

Hers GLP-1 Weight Loss: Gaps in a Fast-Moving Category

GLP-1 receptor agonists are supported by strong trial data. STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001) (Wilding et al., NEJM 2021). That result is real. The clinical question is whether a D2C telehealth subscription reproduces the safety and titration fidelity of the trial protocol.

Formulary and Supply Constraints

Throughout 2023 and 2024, FDA-approved semaglutide (Ozempic, Wegovy) faced significant supply shortages. During shortage periods, many telehealth platforms, including companies in the same competitive space as Hers, pivoted to compounded semaglutide sourced from 503B outsourcing facilities. The FDA removed semaglutide from its drug shortage list in early 2025 (FDA Drug Shortages, 2025), meaning compounded versions can no longer be legally marketed as shortage substitutes. Platforms that still offer compounded semaglutide after that removal are operating in a legally and clinically murky space.

Cardiovascular Screening

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease (Lincoff et al., NEJM 2023). That benefit profile also comes with a contraindication profile. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use GLP-1 agonists (FDA prescribing information, Wegovy). Hers relies on patient self-disclosure for contraindication screening. No platform-mandated lab panel or specialist review is built into the standard GLP-1 onboarding workflow.

Titration Oversight

The standard semaglutide titration schedule runs from 0.25 mg weekly up to 2.4 mg over approximately 16 to 20 weeks, with dose holds for gastrointestinal intolerance. Missing a titration hold can produce nausea, vomiting, and early discontinuation. In the STEP trials, gastrointestinal adverse events caused 4.5% of participants to discontinue semaglutide. Async telehealth follow-up makes proactive titration management harder than a scheduled clinic visit.

Mental Health Prescribing: Real Limitations in a Sensitive Category

Hers prescribes SSRIs and SNRIs for depression and anxiety. Prescribing these medications via telehealth is legal and, in many cases, clinically appropriate. Telehealth psychiatric care has demonstrated non-inferiority to in-person care for mild-to-moderate depression in at least one randomized trial (Fortney et al., Psychiatric Services 2013). The gaps appear at the edges of that evidence base.

Diagnostic Rigor

The PHQ-9 and GAD-7 are validated screening tools, and Hers uses them in intake. Screening is not diagnosis. A score that crosses a clinical threshold on a self-report questionnaire is not equivalent to a structured clinical interview conducted by a licensed psychiatrist or psychologist. The Diagnostic and Statistical Manual criteria for major depressive disorder require clinician judgment about duration, functional impairment, and differential diagnosis. Async intake questionnaires cannot fully replicate that process.

Medication Selection and Monitoring

SSRIs carry a class-wide FDA black-box warning for increased suicidality in patients under 25 (FDA, 2018). Hers treats adult women, so the black-box age threshold is less directly relevant, but the broader point applies: patients initiating antidepressants require follow-up within two to four weeks per American Psychiatric Association guidelines. Whether Hers consistently delivers that follow-up contact through its subscription model is not documented in any published audit.

Referral Pathways

The American College of Obstetricians and Gynecologists recommends that patients with moderate-to-severe depression or suicidal ideation be referred to a mental health specialist (ACOG Practice Bulletin 2018). Hers is not designed to triage to that level of care. Patients with complex psychiatric histories who choose Hers for convenience may not receive the specialist referral their condition warrants.

Hair Loss Treatments: Where Hers Is on Stronger Ground

For hair loss, Hers prescribes topical and oral minoxidil and topical spironolactone, both of which have a reasonable evidence base for female androgenetic alopecia. A 2022 meta-analysis in the Journal of the American Academy of Dermatology found that low-dose oral minoxidil (0.25 to 2.5 mg daily) produced statistically significant improvement in hair density compared to placebo. This is a category where the clinical risk of telehealth prescribing is lower: the medications are not controlled substances, the safety profile is well-characterized, and the monitoring burden is lighter.

Spironolactone Monitoring

Spironolactone is a potassium-sparing diuretic. Even at the lower doses used for hair loss (25 to 100 mg daily), it can raise serum potassium, particularly in patients with renal insufficiency or those taking ACE inhibitors. The Endocrine Society recommends periodic potassium and creatinine monitoring for patients on spironolactone (Endocrine Society Guidelines). Hers does not mandate this monitoring at enrollment.

Hers vs. Alternatives: A Structural Comparison

Hers competes with platforms including Wisp, Midi, Alloy, and traditional integrated telehealth systems. The differentiating factors are formulary breadth, monitoring requirements, and clinician credentials.

Monitoring Standards

Midi, which focuses specifically on perimenopause and menopause, requires lab work before initiating HRT for most patients. Alloy similarly emphasizes baseline hormone panels. Neither platform has published peer-reviewed outcome data either, but their intake workflows more closely mirror the NAMS 2023 clinical guidance, which states that individualized assessment of cardiovascular, breast cancer, and thromboembolic risk should precede hormone therapy initiation. Hers lags on this dimension.

Clinician Credentials and Access

Hers uses a mix of physicians, nurse practitioners, and physician assistants. The prescribing autonomy of NPs and PAs varies by state. In states with restricted NP practice, prescriptions may require physician co-signature, but the patient may never interact with the supervising physician. That is not unique to Hers, but it is worth understanding.

Cost Comparison

Hers subscription costs vary by service category. Mental health subscriptions typically run $25 to $85 per month depending on medication. GLP-1 programs are substantially more expensive, ranging from $199 to $299 per month or more when medication cost is bundled. Traditional in-person endocrinology visits cost $150 to $350 per visit without insurance, but may be covered under most ACA-compliant plans in ways that Hers subscriptions are not.

What the Published Literature Says About D2C Telehealth Quality

No peer-reviewed studies have evaluated Hers specifically. The broader D2C telehealth prescribing literature offers relevant context.

A 2023 study in JAMA Internal Medicine reviewed prescribing patterns across 50 direct-to-consumer telehealth platforms and found that 28% of encounters for acute conditions resulted in antibiotic prescriptions without adequate diagnostic information (Mehrotra et al., JAMA Intern Med 2023). That finding applied to acute care platforms, not hormone therapy specifically, but it illustrates a structural tendency in the D2C model: speed-to-prescription can displace diagnostic rigor.

A 2022 systematic review in BMJ Open examined telehealth safety events and found that inadequate follow-up and monitoring were the most commonly cited contributing factors in adverse outcomes, not errors at the initial prescribing encounter. The implication for Hers patients is that the bigger risk is not the first prescription but what happens over months of use without structured lab review.

Patient-Reported Experience

Hers reviews on third-party platforms such as Trustpilot and Reddit skew toward positive experiences for hair loss and mental health categories, with more mixed feedback for HRT and GLP-1 services. Common complaints center on difficulty reaching clinicians for dose adjustment questions and delays in prescription renewals. These are operational rather than clinical failures, but in categories like GLP-1 titration or antidepressant initiation, operational failures can become clinical ones.

How to Use Hers More Safely

Patients who choose Hers can reduce their clinical risk by following a few concrete steps.

First, obtain baseline labs independently before starting HRT or GLP-1 therapy. A basic panel for HRT candidates should include estradiol, FSH, TSH, lipid panel, and blood pressure measurement. For GLP-1 therapy, HbA1c, fasting glucose, lipid panel, and blood pressure are standard starting points per the American Diabetes Association Standards of Care (ADA Standards of Care 2024).

Second, schedule a follow-up lab draw at three months. This is standard of care for HRT and GLP-1 therapy in brick-and-mortar settings. If Hers does not prompt this, initiate it independently through a local lab or primary care provider.

Third, maintain a parallel relationship with a primary care provider or ob-gyn. Hers works best as a convenience layer on top of existing care, not as a replacement for it. Patients with no primary care provider who use Hers as their sole source of medical oversight are taking on meaningful monitoring risk.

The Menopause Society's 2023 guidelines are direct on this point: "Shared decision-making is essential and requires a discussion of each woman's risk factors and preferences before initiating hormone therapy." A 10-minute async consult does not fully satisfy that standard.